{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:51:22Z","timestamp":1790193082054,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejim.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:49:07Z","timestamp":1519984147000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Vasodilators in acute heart failure - evidence based on new studies"],"prefix":"10.1016","volume":"51","author":[{"given":"Andr\u00e9 M.","family":"Travessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Menezes Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.02.020_bb0005","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0010","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ahj.2010.07.020","article-title":"Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries","volume":"160","author":"Kociol","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/eurjhf\/hfq154","article-title":"Heart Failure Association of ESC (HFA). EURObservational research programme: the heart failure pilot survey (ESC-HF pilot)","volume":"12","author":"Maggioni","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00134-010-2113-0","article-title":"Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF)","volume":"37","author":"Follath","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0030","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.02.020_bb0035","series-title":"National heart failure audit 2011\/12 Annual Report","author":"NICOR","year":"2012"},{"key":"10.1016\/j.ejim.2018.02.020_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.recesp.2014.11.009","article-title":"Acute heart failure: epidemiology, risk factors, and prevention","volume":"68","author":"Farmakis","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.ejim.2018.02.020_bb0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11897-015-0273-5","article-title":"Current approach to decongestive therapy in acute heart failure","volume":"12","author":"Martens","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejim.2018.02.020_bb0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.123","article-title":"The role of intravenous vasodilators in acute heart failure management","volume":"16","author":"Piper","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0065","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0070","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0075","author":"FDA"},{"key":"10.1016\/j.ejim.2018.02.020_bb0080","doi-asserted-by":"crossref","first-page":"31C","DOI":"10.1016\/S0002-9149(96)00186-5","article-title":"Beneficial actions of nitrates in cardiovascular disease","volume":"77","author":"Abrams","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15420\/cfr.2016:3:3","article-title":"Nitrates as a treatment of acute heart failure","volume":"2","author":"Alzahri","year":"2016","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.ejim.2018.02.020_bb0090","article-title":"Nitrates for acute heart failure syndromes","volume":"8","author":"Wakai","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2018.02.020_bb0095","author":"FDA"},{"key":"10.1016\/j.ejim.2018.02.020_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1071-9164(98)90232-9","article-title":"Nitrate therapy is an alternative to furosemide\/morphine therapy in the management of acute cardiogenic pulmonary edema","volume":"4","author":"Beltrame","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.annemergmed.2007.02.022","article-title":"Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis","volume":"50","author":"Levy","year":"2007","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3810\/hp.2011.02.382","article-title":"Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure","volume":"39","author":"Aziz","year":"2011","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.ejim.2018.02.020_bb0115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2796.2009.02146.x","article-title":"Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study","volume":"267","author":"Breidthardt","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0120","doi-asserted-by":"crossref","first-page":"22E","DOI":"10.1016\/0002-9149(88)90085-9","article-title":"Emergency treatment of severe cardiogenic pulmonary edema with intravenous isosorbide-5-mononitrate","volume":"61","author":"Harf","year":"1988","journal-title":"Am J Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2018.02.020_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000174270","article-title":"Isosorbide 5-mononitrate in the treatment of left ventricular failure following acute myocardial infarction","volume":"74","author":"Murray","year":"1987","journal-title":"Cardiology"},{"issue":"Suppl. A","key":"10.1016\/j.ejim.2018.02.020_bb0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/eurheartj\/9.suppl_A.175","article-title":"Haemodynamic effects of intravenous isosorbide-5-mononitrate in acute and chronic left heart failure of ischaemic aetiology","volume":"9","author":"Rabinowitz","year":"1988","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0135","doi-asserted-by":"crossref","first-page":"50J","DOI":"10.1016\/0002-9149(90)91313-U","article-title":"Intravenous isosorbide-5-mononitrate in the treatment of acute myocardial infarction","volume":"65","author":"Rezakovi\u0107","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dosefurosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"351","author":"Cotter","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejim.2018.02.020_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MEJ.0b013e328345d72a","article-title":"Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study","volume":"18","author":"Freund","year":"2011","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0150","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/ejhf.581","article-title":"Bi treatment with hydralazine\/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF)","volume":"18","author":"Sliwa","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0002-9149(81)90618-4","article-title":"Randomized controlled trial of vasodilator therapy after myocardial infarction","volume":"48","author":"Hockings","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0160","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJM198205133061902","article-title":"Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarctioncomplicated by left ventricular failure: results of a veterans administration cooperative study","volume":"306","author":"Cohn","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2008.02.083","article-title":"Sodium nitroprusside for advanced low-output heart failure","volume":"52","author":"Mullens","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0170","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.02.020_bb0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lfs.2017.07.001","article-title":"Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis","volume":"184","author":"Qiu","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.ejim.2018.02.020_bb0180","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.02.020_bb0185","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0190","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.02.020_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0200","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.CIR.94.6.1316","article-title":"Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema","volume":"94","author":"Annane","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.02.020_bb0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000006875","article-title":"Bolus versus continuous low dose of enalaprilat in congestive heart failure with acute refractory decompensation","volume":"91","author":"Podbregar","year":"1999","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2018.02.020_bb0210","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.1995.00430200107014","article-title":"Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises","volume":"155","author":"Hirschl","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0215","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-014-0313-6","article-title":"Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2018.02.020_bb0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ahj.2013.12.023","article-title":"Clevidipine in acute heart failure: results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO)","volume":"167","author":"Peacock","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0225","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2012.11.005","article-title":"Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure(RELAX-AHF) development program: correlation with outcomes","volume":"61","author":"Metra","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0235","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1253\/circj.CJ-15-0227","article-title":"Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure","volume":"79","author":"Sato","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0240","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dosefinding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.02.020_bb0245","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.02.020_bb0250","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ejim.2018.02.020_bb0255","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ejim.2018.02.020_bb0260","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ejim.2018.02.020_bb0265","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"No- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0275","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"COMPOSE investigators and coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0280","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","article-title":"Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications","volume":"191","author":"Potter","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0735-1097(99)00184-9","article-title":"Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial Natrecor Study Group","volume":"34","author":"Mills","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1071-9164(98)90506-1","article-title":"Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brainnatriuretic peptide in patients with hemodynamically decompensated heart failure","volume":"4","author":"Abraham","year":"1998","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0295","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.02.020_bb0300","doi-asserted-by":"crossref","first-page":"227e41","DOI":"10.1177\/107424840400900403","article-title":"Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations","volume":"9","author":"Elkayam","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejim.2018.02.020_bb0305","first-page":"1487e91","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"11","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2018.02.020_bb0310","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ahj.2006.07.002","article-title":"Short and long-term mortality with nesiritide","volume":"152","author":"Arora","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0315","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/clc.20793","article-title":"Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"33","author":"Abraham","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0320","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0325","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2018.02.020_bb0330","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1253\/circj.CJ-07-0760","volume":"72","author":"Nomura","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0335","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heartfailure: the PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circj.69.283","article-title":"Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy","volume":"69","author":"Suwa","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0345","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/fca.15.53","article-title":"Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure","volume":"11","author":"Emani","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ejim.2018.02.020_bb0350","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/ehl337","article-title":"Haemodynamic and clinical effects of ularitide in decompensated heart failure","volume":"27","author":"Mitrovic","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0355","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.02.020_bb0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jchf.2014.09.008","article-title":"Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure)","volume":"3","author":"Felker","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2018.02.020_bb0365","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","article-title":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)","volume":"38","author":"Pang","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2018.02.020_bb0370","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2165\/11592300-000000000-00000","article-title":"Use of nicorandil in cardiovascular disease and its optimization","volume":"71","author":"Horinaka","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2018.02.020_bb0375","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1253\/circj.CJ-11-1110","article-title":"Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome","volume":"76","author":"Ishihara","year":"2012","journal-title":"Circ J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T13:52:03Z","timestamp":1535032323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518300803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":74,"alternative-id":["S0953620518300803"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.02.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasodilators in acute heart failure - evidence based on new studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}